Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan

INTRODUCTION: Tumor necrosis factor inhibitors (TNFi) are commonly used as first-line therapy (biologic disease-modifying antirheumatic drug [bDMARD] and targeted synthetic DMARD [tsDMARD]: defined as targeted therapy) for patients with moderate-to-severe rheumatoid arthritis (RA), usually combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan, Emma, Kershaw, Jim, Blackburn, Stuart, Mahajan, Puneet, Boklage, Susan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410899/
https://www.ncbi.nlm.nih.gov/pubmed/32440826
http://dx.doi.org/10.1007/s40744-020-00211-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410899/
https://www.ncbi.nlm.nih.gov/pubmed/32440826
http://dx.doi.org/10.1007/s40744-020-00211-w

Ejemplares similares